Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
48 Hoursesophagal pH-monitoring With and Without Gaviscon
NCT02783378Completed
- Sponsor
- UZ Brussel
- Start
- Feb 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of magnesium trisilicate in gastroesophageal reflux disease (GERD), sponsored by UZ Brussel. Primary endpoint: Incidence of pathological Gastroesophageal Reflux Disease at 48 hours. Started Feb 2016; status: completed.
02
Drugs
magnesium trisilicate
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02783378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02783378.